Owens & Minor to acquire The Burrows Company
Owens & Minor will pay $30.2 million for the net assets of The Burrows Company and will assume the company’s debt. The final purchase price will be subject
The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.